Oral Administration of Meloxicam Suppresses Low-Dose Endotoxin Challenge-Induced Pain in Thoroughbred Horses.

The research article discusses a study that evaluates the effect of the drug meloxicam on Thoroughbred horses that were administered a certain dose of an endotoxin, lipopolysaccharide (LPS). The findings suggest that meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), has significant potential in reducing pain in these horses.

Research Objectives

The main aim of this study was to examine the effect of meloxicam, an NSAID, on horses subjected to low-dose endotoxin challenge. Previously, other NSAIDs such as flunixin meglumine were used to manage signs of systemic inflammatory conditions but had a detrimental effect on the small intestine mucosa. This study aimed to explore a more appropriate alternative.

• The meloxicam was administered 60 minutes before inducing an inflammatory response with an LPS.
• The effects of the drug were evaluated by assessing several clinical parameters, including body temperature, heart rate, respiratory rate, behavioral pain score, and hoof wall surface temperature.
• The levels of plasma tumor necrosis factor-alpha (an inflammation inducing substance), cortisol, and leukocytes (white blood cells which increase in response to inflammation or infection) were also recorded.

Research Findings

The findings demonstrated that the administration of meloxicam had an analgesic (pain-relieving) effect on the tested horses.

• Pain scores were significantly lower in meloxicam-treated horses at various time points (60, 90, 120 and 180 minutes) after administering the LPS.
• However, there was no significant difference noted in the other parameters assessed, including heart rate, respiration rate, body temperature, information parameters, and blood parameters.
• Therefore, this suggests that administration of meloxicam may have limited systemic effects beyond pain reduction.

Conclusion

The research concluded that meloxicam proved to be effective in reducing pain in horses that were subjected to a low-dose endotoxin challenge. The results of this study indicate the potential to apply meloxicam as an alternative therapeutic method for pain management in equine systemic inflammation cases. However, further research is needed to fully evaluate its effectiveness and examine its long-term impacts on the overall health of the horses.